(ADA) were detected in 6/50 (12%) participants after dosing. ADA had no or minimal impact on PK in all six ADA positive participants. Near-complete CD19 receptor occupancy and an absolute B-cell count nadir of approximately 50% baseline levels were maintained for the duration of the study...
Memory B cellsChildren with Down syndrome (DS) have a high incidence of recurrent respiratory tract infections, leukaemia and autoimmune disorders, suggesting immune dysfunction. The present study evaluated the role of the CD19 complex and memory B cells in the pathogenesis of immunodeficiency in ...
T cells engineered with chimeric antigen receptors (CARs) targeting the transmembrane protein CD19 have varied success in the treatment of B cell cancers. Response rates in pediatric patients with acute lymphoblastic leukemia (ALL) are high, with >85% achieving complete remission within 1 month of...
For long-term killing assays, CAR T cells were combined with target cancer cells at an E:T ratio of 0.125:1 or 0.0625:1, and co-cultures were evaluated for absolute counts of T cells and cancer cells by flow cytometry using CountBright absolute counting beads (ThermoFisher; Cat# C36950)...
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. In this study, we systematically analyzed CD19 CAR-T...
After mixing well, cells were centrifuged. This washing step was repeated. After the supernatant was aspirated completely, the cell pellet was dissolved in 100 μl PEB buffer, and 100 μl Precision Count Beads™ were added. For CD19+ B-cell population detection, 100 μl whole blood sample...
This study included 11 pediatric patients (< 16 years old) newly diagnosed with pre-B ALL by examining the morphology of and immunophenotyping cells from PB samples or BM aspirates. The samples were stratified into two subgroups: high risk (0–12 months or > 10 years old; leucocyte ...
patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-generation chimeric antigen (Ag) receptor specific to the B-cell lineage Ag CD...
[IV] daily for 2 days). In addition, 7% of patients in JULIET did not receive any LDC if their white blood cell count was ≤ 1000 cells/µL within 1 week prior to tisa-cel infusion [21]. In a post-hoc analysis of the JULIET trial, patients who received Flu/Cy LDC ...
Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL ...